Haleon plc(HLN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported organic sales growth of 3% for 2025, which was below expectations due to a slowdown in the U.S. market and a weaker cold and flu season [8][9] - Gross margin improved by 220 basis points, contributing to high single-digit operating growth at constant currency [10][44] - The company anticipates organic sales growth guidance of 3%-5% for 2026, indicating a potential sequential acceleration [6][11] Business Line Data and Key Metrics Changes - The U.S. market experienced a decline of approximately 0.5%, while APAC and EMEA LatAm grew in the mid-single digits [8] - Oral health business showed strong performance, helping to offset declines in the cold and flu category [9][20] - The company plans to focus on driving category growth through investments in advertising and promotion (A&P) and innovation [10][12] Market Data and Key Metrics Changes - Emerging markets, particularly India and China, are expected to contribute significantly to growth, with India showing double-digit growth and strong performance in oral health [29][31] - The company noted a slowdown in LATAM, particularly in Q4, due to challenging macroeconomic conditions [30] - E-commerce is growing rapidly in China, with online sales accounting for around 40% of the business [29] Company Strategy and Development Direction - The company has restructured its leadership to enhance agility and drive growth, creating roles such as Chief Growth Officer and Chief Transformation Officer [15][18] - A focus on unlocking growth through streamlined operations and improved commercial execution is emphasized [15][17] - The company aims to invest in innovation and capabilities while maintaining a leaner organizational structure [18][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth in the U.S. market in 2026, despite current challenges [9][12] - The company acknowledges the uncertain market environment but remains optimistic about long-term growth potential in attractive categories [12][68] - Management highlighted the importance of cold and flu products in the overall portfolio and their role in driving consumer health [56] Other Important Information - The company is focusing on improving its supply chain efficiency, which has contributed to gross margin improvements [44][46] - A significant portion of A&P investment is directed towards oral health and emerging markets, reflecting strategic priorities [75] Q&A Session Summary Question: What are the main drivers behind the organic sales growth guidance of 3%-5% for 2026? - Management indicated that the guidance reflects expectations of market improvement and a focus on driving category growth through investments and innovation [6][11] Question: Can you discuss the new reorganization and its impact on growth in the U.S.? - The reorganization aims to enhance agility and streamline operations, with new leadership roles expected to drive volume growth and innovation [15][18] Question: How is the performance in emerging markets, and what areas are underperforming? - Emerging markets are performing well, particularly in India, while LATAM has faced challenges due to macroeconomic conditions [30][31] Question: How does the company plan to balance top-line performance with margin improvement? - Management emphasized the importance of investing in growth while achieving margin improvements through supply chain efficiencies [35][44] Question: What is the outlook for the cold and flu business and its importance in securing shelf space? - The cold and flu category is considered crucial for consumer health, and management believes it will play an important role in future growth [56]